EUVIMEDEUVIMED entdecken
Open Access

Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction

Sara Ovejero, Laura Alibert, Julie Devin, Tatiana Cañeque, Valentin Jacquier, Andrea Romero, Salome Amar, Matthieu Abouladze, Elvira Garcia de Paco, Ouissem Karmous Gadacha, Guilhem Requirand, Nicolas Robert und 9 weitere

Theranostics · 03.02.2025 · 15 (7) · 2834-2851

DOI: 10.7150/thno.101821 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, erschienen am 03.02.2025. Verfasst von Sara Ovejero und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Human Genetics UMR 9002 CNRS-UM, Montpellier, France. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Iron. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Mantle-cell lymphoma (MCL) remains an aggressive and incurable cancer.Accumulating evidence reveals that abnormal iron metabolism plays an important role in tumorigenesis and in cancer progression of many tumors.Based on these data, we searched to identify alterations of iron homeostasis in MCL that could be exploited to develop novel therapeutic strategies.

Methods

Analysis of the iron metabolism gene expression profile of a cohort of patients with MCL enables the identification of patients with a poor outcome who might benefit from an iron homeostasis-targeted therapy.We analyzed the therapeutic interest of ironomycin, known to sequester iron in the lysosome and to induce ferroptosis.

Results

In a panel of MCL cell lines, ironomycin inhibited MCL cell growth at nanomolar concentrations compared with conventional iron chelators.Ironomycin treatment resulted in ferroptosis induction and decreased cell proliferation rate, with a reduced percentage of cells in S-phase together with Ki67 and Cyclin D1 downregulation.Ironomycin treatment induced DNA damage response, accumulation of DNA double-strand breaks, and activated the Unfolded Protein Response (UPR).We validated the therapeutic interest of ironomycin in primary MCL cells of patients.Ironomycin demonstrated a significant higher toxicity in MCL cells compared to normal cells from the microenvironment.We tested the therapeutic interest of combining ironomycin with conventional treatments used in MCL.We identified a synergistic effect when ironomycin is combined with Ibrutinib, Bruton's tyrosine kinase (BTK) inhibitor, associated with a strong inhibition of B-Cell receptor (BCR) signaling.

Conclusion

Altogether, these data underline that MCL patients my benefit from targeting iron homeostasis using ironomycin alone or in combination with conventional MCL treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellIronHumansCell Line, TumorCell ProliferationFerroptosisUnfolded Protein ResponsePyrazolesPyrimidinesIron Chelating AgentsAdeninePiperidines

Stichwörter der Autor:innen

B-cell receptor signalingdrug combinationiron metabolismironomycinmantle cell lymphoma

Substanzen

IronibrutinibPyrazolesPyrimidinesIron Chelating AgentsAdeninePiperidines

Autor:innen und Institutionen

  • Institute of Human Genetics UMR 9002 CNRS-UM, Montpellier, France.
  • Department of Biological Hematology, CHU Montpellier, Montpellier, France.
  • Chemical Biology of Cancer Laboratory, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, France; PSL Université, Paris, France; CNRS UMR 3666, Paris, France; INSERM U1143, Paris, France.
  • Diag2Tec, Montpellier, France.
  • Department of Clinical Hematology, CHU Montpellier, Montpellier, France.
  • CNRS UMR 5535, University of Montpellier, Montpellier, France.

Zitieren

APA

Ovejero, S., Alibert, L., Devin, J., Cañeque, T., Jacquier, V., Romero, A., Amar, S., Abouladze, M., de Paco, E. G., Gadacha, O. K., Requirand, G., Robert, N., Zellagui, M. L., de Boussac, H., Cartron, G., Chiche, J., Ricci, J. E., Herbaux, C., Rodriguez, R., …, & Bret, C. (2025). Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction. Theranostics, 15(7), 2834-2851. https://doi.org/10.7150/thno.101821

Vancouver

Ovejero S, Alibert L, Devin J, Cañeque T, Jacquier V, Romero A, et al. Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction. Theranostics. 2025;15(7):2834-2851. doi:10.7150/thno.101821

BibTeX
@article{Ovejero2025,
  author = {Ovejero, Sara and Alibert, Laura and Devin, Julie and Cañeque, Tatiana and Jacquier, Valentin and Romero, Andrea and Amar, Salome and Abouladze, Matthieu and de Paco, Elvira Garcia and Gadacha, Ouissem Karmous and Requirand, Guilhem and Robert, Nicolas and Zellagui, Miss Leriem and de Boussac, Hugues and Cartron, Guillaume and Chiche, Johanna and Ricci, Jean-Ehrland and Herbaux, Charles and Rodriguez, Raphael and Moreaux, Jerome and Bret, Caroline},
  title = {Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction},
  journal = {Theranostics},
  year = {2025},
  volume = {15},
  number = {7},
  pages = {2834--2851},
  doi = {10.7150/thno.101821}
}
Kostenlos starten →